Table 1

Characteristics of primary Sjögren's syndrome patients

EULAR cohort (N=395)ASSESS cohort (N=395)
Age (years)57.5 [46–66]58 [51–67]
Sex (female)378 (95.7%)370 (93.6%)
Disease duration (years)6 [2–12]5 [2–9]
Decrease in salivary flow286 (72.6%)162/327 (47.9%)
Positive salivary gland biopsy (focus score ≥1)250/259 (96.5%)318/352 (87.8%)
Autoantibodies
 Anti-SSA313 (79.4%)234 (59.2%)
 Anti-SSB202 (51.3%)132 (33.5%)
Current or previous systemic involvement251 (63.7%)135 (65.0%)
Current systemic involvement145 (36.8%)122 (30.9%)
Present salivary gland swelling87 (22.9%)45 (11.4%)
Current treatment
 Corticosteroids96 (24.3%)94 (23.7%)
 Hydroxychloroquine115 (29.1%)121 (23.7%)
 Azathioprine13 (3.3%)6 (1.5%)
 Methotrexate16 (4.1%)20 (5.1%)
 Rituximab12 (3.0%)4 (1.0%)
Disease activity indexes
 ESSDAI6 [2–12]2 [0–7]
 ESSPRI6 [4.3–7.3]5.7 [4–7]
  • Results are expressed as median [IQR] and mean±SD or number (%).

  • ASSESS, Assessment of Systemic Signs and Evolution of SS; EULAR, European League Against Rheumatism; ESSDAI, EULAR Sjögren's syndrome disease activity index; ESSPRI, EULAR Sjögren's syndrome patient-reported index.